摘要
目的探讨广州地区汉族心血管病患者CYP2C19~* 1、CYP2C19~* 17基因多态性的频率分布及其对氯吡格雷疗效的影响。方法选取中山大学孙逸仙纪念医院2015年4月16日-2016年5月12日648例汉族心血管病住院患者,采用双探针实时荧光PCR法测定CYP2C19~* 1、CYP2C19~* 17基因型。选出符合纳入标准的167例,比较CYP2C19~* 1、CYP2C19~* 17基因型患者的血小板聚集率。结果广州地区汉族心血管病患者中CYP2C19~* 1~* 1基因频率为98.30%(637/648),CYP2C19~* 1~* 17基因频率为1.70%(11/648),无纯合突变。CYP2C19~* 1~* 17基因型患者服用氯吡格雷后血小板聚集率低于CYP2C19~* 1~* 1基因型组,差异有统计学意义(P<0.05)。结论广州汉族人群中,携带CYP2C19~* 17基因型的心血管病患者可增加出血的风险,基因检测有助于完善个体化合理用药。
Objective To evaluate the impact of CYP2C19*1 and CYP2C19*17 polymorphisms in the clopidogrel efficacy in patients with cardiovascular disease in Guangzhou. Methods 648 cases of hospitalized Han patients with cardiovascular disease were selected from Sun Yat-sen Memorial Hospital from April 16 th,2015 to May 12,2016. Determination of CYP2C19*1 and CYP2C19*17 polymorphisms was performed using double probe real-time fluorescence PCR,and 167 of them were selected in accordance with the inclusive criteria. Then we compared the platelet aggregation rate between CYP2C19*17 alleles carriers and non-carriers. Results In Han patients with cardiovascular disease in Guangzhou,the CYP2C19*1*1 gene frequency was98. 30%( 637/648),CYP2C19*1*17 gene frequency was 1. 70%( 11/648),respectively,and homozygous mutation wasn't found. The platelet aggregation rate in CYP2C19*1*17 alleles carriers was lower than CYP2C19*1*1,with the differences statistically significant( P 〈0. 05). Conclusion Han patients with cardiovascular disease in Guangzhou carrying CYP2C19*17allele should be aware of bleeding events when using clopidogrel. Genetic testing contributes to the improvement of individual rational drug use.
出处
《中国卫生检验杂志》
CAS
2017年第13期1831-1833,1837,共4页
Chinese Journal of Health Laboratory Technology
基金
教育部留学回国人员科研启动基金资助项目(教外司留[2015]1098号)
广东省自然科学基金资助项目(2016A030313345)